Login / Signup

GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Amanda N LisbyJohn C FlickingerBabar BashirMegan WeindorferSanjna ShelukarMadison CrutcherAdam E SnookScott A Waldman
Published in: Expert review of precision medicine and drug development (2021)
The GUCY2C biomarker has multi-faceted utility in medicine. Developmental investment of GUCY2C as a diagnostic and therapeutic biomarker offers a variety of options taking the molecular characteristics of cancer into account. From GUCY2C-targeted therapies, namely cancer vaccines, CAR-T cells, and monoclonal antibodies, to GUCY2C agonists for chemoprevention in those who are at high risk for developing colorectal cancer, the utility of this protein provides many avenues for exploration with significance in the field of precision medicine.
Keyphrases
  • papillary thyroid
  • squamous cell
  • lymph node metastasis
  • squamous cell carcinoma
  • young adults
  • protein protein
  • single molecule
  • amino acid